The content on this site is intended for healthcare professionals only
Dr Liesbeth Lenaerts talks to ecancer at ESMO 2018 about a pre-existing pre-natal test which flagged up copy number alterations and cancer in the foetus' parents.
The test was then developed and trialled on elderly patients and it was further verified that this test could detect cancer in most of those patients.
Dr Lenaerts goes into more depth about the nature of these copy number alterations.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
The added value of integrative medicine
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma in a resource constrained setting
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems
SABCS 2023: Latest breast cancer diagnostics guidelines
